首页> 外文期刊>Molecular cancer therapeutics >Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.
【24h】

Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.

机译:用可诱导的Gal4-> Fluc转基因报告基因小鼠监测雷帕霉素在体内的分子特异性药效学。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Rapamycin (Rap), a small-molecule inhibitor of mTOR, is an immunosuppressant, and several Rap analogues are cancer chemotherapeutics. Further pharmacologic development will be significantly facilitated if in vivo reporter models are available to enable monitoring of molecular-specific pharmacodynamic actions of Rap and its analogues. Herein we present the use of a Gal4-->Fluc reporter mouse for the study of Rap-induced mTOR/FKBP12 protein-protein interactions in vivo with the use of a mouse two-hybrid transactivation strategy, a derivative of the yeast two-hybrid system applied to live mice. Upon treatment with Rap, a bipartite transactivator was reconstituted, and transcription of a genomic firefly luciferase reporter was activated in a concentration-dependent (K(d) = 2.3 nmol/L) and FK506-competitive (K(i) = 17.1 nmol/L) manner in cellulo, as well as in a temporal and specific manner in vivo. In particular, after a single dose of Rap (4.5 mg/kg, i.p.), peak Rap-induced protein-protein interactions were observed in the liver at 24 hours post treatment, with photon flux signals 600-fold over baseline, which correlated temporally with suppression of p70S6 kinase activity, a downstream effector of mTOR. The Gal4-->Fluc reporter mouse provides an intact physiologic system to interrogate protein-protein interactions and molecular-specific pharmacodynamics during drug discovery and lead characterization. Imaging protein interactions and functional proteomics in whole animals in vivo may serve as a basic tool for screening and mechanism-based analysis of small molecules targeting specific protein-protein interactions in human diseases.
机译:雷帕霉素(Rap)是mTOR的小分子抑制剂,是一种免疫抑制剂,几种Rap类似物是癌症的化学治疗剂。如果可以使用体内报告基因模型来监测Rap及其类似物的分子特异性药效作用,将大大促进进一步的药理学发展。在本文中,我们介绍了使用Gal4-> Fluc报告基因小鼠,利用小鼠双杂交反式激活策略(酵母双杂交的衍生物)研究Rap诱导的体内mTOR / FKBP12蛋白相互作用。系统应用于活体小鼠。经Rap处理后,重组了二部分反式激活剂,并以浓度依赖性(K(d)= 2.3 nmol / L)和FK506竞争性(K(i)= 17.1 nmol / L)以纤维素的方式,以及体内的时间和特异性方式。特别是,在单剂Rap(4.5 mg / kg,ip)后,治疗后24小时在肝脏中观察到Rap诱导的蛋白质-蛋白质相互作用峰值,光子通量信号比基线高600倍,这在时间上相关具有抑制mTOR下游效应物p70S6激酶活性的作用。 Gal4-> Fluc报告基因小鼠提供了完整的生理系统,可在药物发现和前导特征鉴定过程中询问蛋白质-蛋白质相互作用和分子特异性药效学。对整个动物体内的蛋白质相互作用和功能蛋白质组学进行成像,可以作为针对人类疾病中针对特定蛋白质-蛋白质相互作用的小分子进行筛选和基于机理分析的基本工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号